Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

被引：0
|
作者：
Ren, S. [1 ]
Wang, X. [2 ]
Han, B. [3 ]
Pan, Y. [4 ]
Zhao, J. [5 ]
Cheng, Y. [6 ,10 ]
Hu, S. [7 ]
Liu, T. [8 ]
Li, Y. [9 ]
Cheng, Y. [6 ,10 ]
Feng, J. [11 ]
Yi, S. [12 ]
Gu, S. [13 ]
Gao, S. [14 ]
Luo, Y. [15 ,16 ]
Liu, Y. [17 ]
Liu, C. [18 ]
Duan, H. [19 ]
Zhou, C. [1 ]
Fan, J. [20 ]
机构：
[1] Shanghai Pulm Hosp, Oncol Dept, Shanghai, Peoples R China
[2] Guangdong Pharmaceut Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Shanghai Chest Hosp, Dept Resp, Shanghai, Peoples R China
[4] USTC, Oncol Chemotherapy Dept, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
[5] Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China
[6] Shandong Univ, Dept Chemotherapy, Qilu Hosp, Jinan, Peoples R China
[7] Hubei Canc Hosp, Dept Thorac Tumor, Wuhan, Peoples R China
[8] Fudan Univ, Dept Med Oncol, Med Oncol Dept, Zhongshan Hosp, Shanghai, Peoples R China
[9] Sichuan Univ, Resp & Crit Care Med, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[10] Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[11] Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Affiliated Canc Hosp, Nanjing, Peoples R China
[12] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[13] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China
[14] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[15] Cent South Univ, Thorac Med Dept, Hunan Canc Hosp, Changsha, Peoples R China
[16] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[17] Zhengzhou Univ, Henan Canc Hosp, Dept Gastroenterol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[18] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China
[19] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[20] Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43P
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [1] First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
    Ren, Shengxiang
    Wang, Xicheng
    Han, Bao-Hui
    Pan, Yueyin
    Zhao, Jun
    Cheng, Yufeng
    Hu, Sheng
    Liu, Tianshu
    Li, Yalun
    Cheng, Ying
    Feng, Jifeng
    Yi, Shanyong
    Gu, Shanzhi
    Gao, Shegan
    Luo, Yongzhong
    Liu, Ying
    Liu, Caigang
    Duan, Huijie
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    Zhou, Caicun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
  • [2] Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
    Qu, Yuan-Yuan
    Zhang, Hai-Liang
    Guo, Hongqian
    Luo, Hong
    Zou, Qing
    Xing, Nianzeng
    Xia, Shujie
    Sun, Zhongquan
    Zhang, Xuepei
    He, Chaohong
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Ding-Wei
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5838 - 5846
  • [3] Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
    Ren, Shengxiang
    Xiong, Anwen
    Yu, Jia
    Wang, Xicheng
    Han, Baohui
    Pan, Yueyin
    Zhao, Jun
    Cheng, Yufeng
    Hu, Sheng
    Liu, Tianshu
    Li, Yalun
    Cheng, Ying
    Feng, Jifeng
    Yi, Shanyong
    Gu, Shanzhi
    Gao, Shegan
    Luo, Yongzhong
    Liu, Ying
    Liu, Caigang
    Duan, Huijie
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    Zhou, Caicun
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [4] Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.
    Liu, Tianshu
    Yang, Mudan
    Li, Jin
    Pan, Yueyin
    Yuan, Ying
    Yi, Shanyong
    Wang, Junsheng
    Cheng, Ying
    Feng, Jifeng
    Gao, Shegan
    Wang, Xicheng
    Qu, Song
    Zhang, Xizhi
    Lu, Jin
    Xiu, Peng
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.
    Chen, Ming-Yuan
    Chen, Xiaozhong
    Zhang, Ximei
    Liu, Tianshu
    Wang, Xicheng
    Cai, Jinling
    Wang, Shuni
    Chen, Chunxia
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18031 - E18031
  • [6] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, Shengxiang
    He, Jianxing
    Fang, Yong
    Chen, Gongyan
    Ma, Zhiyong
    Chen, Jianhua
    Guo, Renhua
    Lin, Xiaoyan
    Yao, Yu
    Wu, Gang
    Wang, Quanren
    Zhou, Caicun
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
  • [7] Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.
    Qu, Yuan-Yuan
    Guo, Hongqian
    Luo, Hong
    Zou, Qing
    Xing, Ninazeng
    Sun, Zhongquan
    Zhang, Xuepei
    Xia, Shujie
    He, Chaohong
    Zhang, Hailiang
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] An indirect Comparison of Pembrolizumab plus Chemo vs Ipilimumab plus Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Insinga, R.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S23
  • [9] An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab plus Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Insinga, R.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S24
  • [10] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
    Wu, Y.
    Zhang, L.
    Fan, Y.
    Zhou, J.
    Zhang, L.
    Zhou, Q.
    Li, W.
    Hu, C.
    Chen, G.
    Zhang, X.
    Zhou, C.
    Dang, T.
    Penrod, J.
    Kush, D.
    Qin, Y.
    Li, B.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
12345